Delving into the Latest Updates on Anti-human thymocyte equine immunoglobulin(Pfizer) with Synapse

Overview

Basic Info

Drug Type

Antitoxin

Synonyms

ATGAM, アトガム

Target-

Action

inhibitors

Mechanism

Thymocyte inhibitors

Therapeutic Areas

Hemic and Lymphatic DiseasesOther Diseases

Active Indication

Anemia, Aplastic

Inactive Indication-

Originator Organization

Pfizer Japan, Inc.

Active Organization

Pfizer Japan, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (27 Mar 2023),

Anemia, Aplastic

Regulation-

Login to view timeline

The objective of this study is to confirm the safety of ATGAM in patients with moderate to severe aplastic anemia under the actual use in Japan.
The registration criteria is patients with moderate to severe aplastic anemia who receive ATGAM.
The observation period is 24 weeks (6 months) from the start of administration (Day 1). However, in cases where treatment has been completed or discontinued less than 24 weeks after the start of administration, observation is continued until completion (discontinuation) of treatment.

Start Date21 Feb 2024

Sponsor / Collaborator

Pfizer Inc.

NCT04862221

/ RecruitingPhase 2IIT

A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial with Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin As Treatment for Acute Liver Failure in Pediatric Patients

TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.

Start Date09 Feb 2022

Sponsor / Collaborator

National Institute of Diabetes & Digestive & Kidney Diseases

[+1]

100 Clinical Results associated with Anti-human thymocyte equine immunoglobulin(Pfizer)

Login to view more data

100 Translational Medicine associated with Anti-human thymocyte equine immunoglobulin(Pfizer)

Login to view more data

100 Patents (Medical) associated with Anti-human thymocyte equine immunoglobulin(Pfizer)

Login to view more data

1

Literatures (Medical) associated with Anti-human thymocyte equine immunoglobulin(Pfizer)

01 May 1990·Boletin de la Asociacion Medica de Puerto Rico

Therapy for pediatric aplastic anemia; 7 years experience at the Puerto Rico Pediatric Oncology Program.

Article

Author: Clavell, L A ; Montalvo, F W ; Casanova, R

Nine pediatric patients with aplastic or hypoplastic anemia were seen at the Pediatric Hematology-Oncology service of the University of Puerto Rico, from 1980 to first trimester of 1987. Included were eight males and one female ranging from twenty months to sixteen 8/12 years (mean 13 years). Hematomas and fever were the most common complaints. The interval since the first symptoms and the diagnosis varied from one day to one week. The peripheral cell count was abnormal in all patients; pancytopenia being the most common finding. Five of seven who received antithymocyte globulin (ATG-AM), showed improvement in their peripheral count. The median time interval from the end of ATG-AM and response was two months (range 2 weeks to 15 months).

100 Deals associated with Anti-human thymocyte equine immunoglobulin(Pfizer)

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anemia, Aplastic	Japan	Pfizer Japan, Inc.	27 Mar 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data